Seminars in Nuclear Medicine
Volume 31, Issue 1 , Pages 28-49 , January 2001

Quantitative studies of bone with the use of 18F-fluoride and 99mTc-methylene diphosphonate

References 

  1. Einhorn TA. The bone organ system: Form and function. In: Marcus R, Feldman D, Kelsey J editor. Osteoporosis. San Diego, CA: Academic Press; 1996;p. 3–22
  2. Baron R. Anatomy and ultrastructure of bone. In: Favus MJ editors. Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism. ed 4. Philadelphia, PA: Lippincott Williams & Wilkins; 1999;p. 3–10
  3. Sabatier JP, Guaydier-Souquieres G, Benmalek A, et al. Evolution of lumbar bone mineral content during adolescence and adulthood: A longitudinal study in 395 healthy females 10–24 years of age and 206 premenopausal women. Osteoporos Int. 1999;9:476–482
  4. Bass S, Delmas PD, Pearce G, et al. The differing tempo of growth in bone size, mass, and density is region-specific. J Clin Invest. 1999;104:795–804
  5. Hui SL, Zhou L, Evans R, et al. Rates of growth and loss of bone mineral in the spine and femoral neck in white females. Osteoporos Int. 1999;9:200–205
  6. In: WHO Technical Report Series 843. Geneva: World Health Organization; 1994;
  7. In: Consensus Development Conference: Diagnosis, prophylaxis and treatment of osteoporosis. Am J Med. 94:1993;p. 646–650
  8. Khosla S, Kleerekoper M. Biochemical markers of bone turnover. In: Favus MJ editors. Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism. ed 4. Philadelphia, PA: Lippincott Williams & Wilkins; 1999;p. 128–134
  9. Garnero P, Delmas PD. Measurements of biochemical markers: Methods and limitations. In: Bilezikian JP, Raisz LG, Rodan GA editor. Principles of Bone Biology. San Diego, CA: Academic Press; 1996;p. 1277–1291
  10. Seibel MJ, Pols HAP. Clinical applications of biochemical markers of bone metabolism. In: Bilezikian JP, Raisz LG, Rodan GA editor. Principles of Bone Biology. San Diego, CA: Academic Press; 1996;p. 1293–1311
  11. Garnero P, Weichung JS, Gineyts E, et al. Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment. J Clin Endocrinol Metab. 1994;79:1693–1700
  12. Beck-Jensen JE, Kollerup G, Sorensen HA, et al. A single measurement of biochemical markers of bone turnover has limited utility in the individual person. Scand J Clin Lab Invest. 1997;57:351–359
  13. Recker RR. Bone biopsy and histomorphometry in clinical practice. In: Favus MJ editors. Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism. ed 4. Philadelphia, PA: Lippincott Williams & Wilkins; 1999;p. 169–174
  14. Miller PD, Bonnick SL. Clinical applications of bone densitometry. In: Favus MJ editors. Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism. ed 4. Philadelphia, PA: Lippincott Williams & Wilkins; 1999;p. 152–159
  15. Blake GM, Fogelman I. Technical principles of dual energy X-ray absorptiometry. Semin Nucl Med. 1997;27:210–228
  16. Eastell R. Treatment of postmenopausal osteoporosis. N Engl J Med. 1998;338:736–746
  17. Blake GM, Fogelman I. Interpretation of bone densitometry studies. Semin Nucl Med. 1997;27:248–260
  18. Jung A, Bartholdi P, Mermillod B, et al. Critical analysis of methods for analysing human calcium kinetics. J Theor Biol. 1978;73:131–157
  19. Weaver CM. Use of calcium tracers and biomarkers to determine calcium kinetics and bone turnover. Bone. 1998;22(suppl 5):103S–104S
  20. Marshall JH, Lloyd EL, Rundo J, et al. Alkaline earth metabolism in adult man. Health Phys. 1973;24:125–221
  21. Subramanian G, McAfee JG, Blair RJ, et al. Technetium-99m-methylene disphosphonate—A superior agent for skeletal imaging: Comparison with other technetium complexes. J Nucl Med. 1975;16:744–755
  22. Blau M, Ganatra R, Bender MA. 18F-fluoride for bone imaging. Semin Nucl Med. 1972;2:31–37
  23. Peters AM. Bone turnover in osteoporosis. In: Schoutens A, Arlet J, Gardeniers JWM, et al. editor. Bone Circulation and Vascularization in Normal and Pathological Conditions. New York, NY: Plenum Press; 1993;p. 177–183
  24. Lin JH. Bisphosphonates: A review of their Pharmacokinetics properties. Bone. 1996;18:75–85
  25. Subramanian G. Radiopharmaceuticals for bone scanning. In: Fogelman I, Collier D, Rosenthall L editor. Skeletal Nuclear Medicine. St Louis, MO: Mosby; 1996;p. 9–20
  26. Russell RG, Rogers MJ. Bisphosphonates: From the laboratory to the clinic and back again. Bone. 1999;25:97–106
  27. Jones AG, Francis MD, Davis MA. Bone scanning: Radionuclidic reaction mechanisms. Semin Nucl Med. 1976;6:3–18
  28. Davis MA, Jones AG. Comparison of 99mTc-labeled phosphate and phosphonate agents for skeletal imaging. Semin Nucl Med. 1976;6:19–31
  29. Francis MD, Russell RGG, Fleisch H. Diphosphonates inhibit formation of calcium phosphate crystals in vitro and pathological calcification in vivo. Science. 1969;165:1264–1266
  30. Siris ES. Paget's disease of bone. In: Favus MJ editors. Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism. ed 4. Philadelphia, PA: Lippincott Williams & Wilkins; 1999;p. 415–452
  31. Mundy GR, Martin TJ. The hypercalcaemia of malignancy: Pathogenesis and treatment. Metabolism. 1982;31:1247–1277
  32. Liberman UA, Weiss SR, Broll J, et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med. 1995;333:1437–1443
  33. Mortensen L, Charles P, Bekker PJ, et al. Risedronate increases bone mass in an early postmenopausal population: Two years of treatment plus one year of follow-up. J Clin Endocrinol Metab. 1998;83:396–402
  34. Black DM, Cummings SR, Karpf DB, et al. Randomized trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet. 1996;348:736–746
  35. Reginster J-Y, Minne HW, Sorensen OH, et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Osteoporos Int. 2000;11:83–91
  36. Hortobagyi GN, Theriault RL, Porter L, et al. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. N Engl J Med. 1996;335:1785–1791
  37. Hamdy NAT, Papapoulos SE. The palliative management of skeletal metastases in prostate cancer: Use of boneseeking radionuclides and bisphosphonates. Semin Nucl Med. 2001;31:62–68
  38. Hyldstrup L, McNair P, Ring P, et al. Studies on diphosphonate kinetics. Part I: Evaluation of plasma elimination curves during 24 h. Eur J Nucl Med. 1987;12:581–584
  39. Hyldstrup L, McNair P, Ring P, et al. Studies on diphosphonate kinetics. Part II: Whole body bone uptake rate during constant infusion—A refined index of bone metabolism. Eur J Nucl Med. 1987;12:585–588
  40. Nisbet AP, Edwards S, Lazarus CR, et al. Chromium-51 EDTA/technetium-99m-MDP plasma ratio to measure total skeletal function. Br J Radiol. 1984;57:677–680
  41. Whitford GM. Intake and metabolism of fluoride. Adv Dent Res. 1994;8:5–14
  42. Edelman IS, Leibman J. Anatomy of body water and electrolytes. Am J Med. 1959;27:256–277
  43. Pierson RN, Price DC, Wang J, et al. Extracellular water measurements: Organ tracer kinetics of bromide and sucrose in rats and man. Am J Physiol. 1978;235:F254–F264
  44. Staffurth JS, Birchall I. The measurement of the extracellular fluid volume with radioactive bromine. Clin Sci. 1960;19:45–53
  45. Tosteson DC. Halide transport in red blood cells. Acta Physiol Scand. 1959;46:19–41
  46. Hosking DJ, Chamberlain MJ. Studies in man with 18F. Clin Sci. 1972;42:153–161
  47. Wootton R, Dore C. The single-passage extraction of 18F in rabbit bone. Clin Phys Physiol Meas. 1986;7:333–343
  48. Hawkins RA, Choi Y, Huang S-C, et al. Evaluation of the skeletal kinetics of fluorine-18-fluoride ion with PET. J Nucl Med. 1992;33:633–642
  49. Chen PS, Smith FA, Gardiner DE, et al. Renal clearance of fluoride. Proc Soc Exp Biol Med. 1956;92:879–883
  50. Carlson CH, Armstrong WD, Singer L. Distribution, migration and binding of whole blood fluoride evaluated with radiofluoride. Am J Physiol. 1960;199:187–189
  51. Taves DR. Electrophoretic mobility of serum fluoride. Nature. 1968;220:582–583
  52. Whitford GM, Pashley DH, Stringer GI. Fluoride renal clearance: A pH-dependent event. Am J Physiol. 1976;230:527–532
  53. Ekstrand J, Ehrnebo M, Boreus LO. Fluoride bioavailability after intravenous and oral administration: Importance of renal clearance and urine flow. Clin Pharmacol Ther. 1978;23:329–337
  54. Ekstrand J, Spak CJ, Ehrnebo M. Renal clearance of fluoride in a steady state condition in man: Influence of urinary flow and pH changes by diet. Acta Pharmacol Toxicol. 1982;50:321–325
  55. Ekstrand J, Spak CJ. Fluoride pharmacokinetics: Its implications in the fluoride treatment of osteoporosis. J Bone Miner Res. 1990;5(suppl 1):S53–S61
  56. Fogelman I, Bessent RG, Turner JG, et al. The use of whole-body retention of Tc-99m disphosphonate in the diagnosis of metabolic bone disease. J Nucl Med. 1978;19:270–275
  57. Fogelman I, Bessent RG, Cohen HN, et al. Skeletal uptake of disphosphonate. Method for prediction of postmenopausal osteoporosis. Lancet. 1980;2:667–670
  58. Fogelman I, Bessent RG, Beastall G, et al. Estimation of skeletal involvement in primary hyperparathyroidism. Ann Int Med. 1980;92:65–67
  59. Fogelman I, Bessent R. Age-related alterations in skeletal metabolism—24-hr whole-body retention of disphosphonate in 250 normal subjects: Concise communication. J Nucl Med. 1982;23:296–300
  60. Caniggia A, Vattimo A. Kinetics of technetium-99m-tinmethylene-diphosphonate in normal subjects and pathological conditions: A simple index of bone metabolism. Calcif Tissue Int. 1980;30:5–13
  61. Fogelman I, Martin W. Assessment of skeletal uptake of Tc-99m disphosphonate over a five-day period. Eur J Nucl Med. 1983;8:489–490
  62. Fogelman I, Bessent R, Scullion JE, et al. Accuracy of 24-h whole-body (skeletal) retention of diphosphonate measurements. Eur J Nucl Med. 1982;7:359–363
  63. Martin W, Fogelman I, Bessent RG. Measurement of 24-hour whole-body retention of Tc-99m HEDP by a gamma camera. J Nucl Med. 1981;22:542–545
  64. Hyldstrup L, Mogensen N, Jensen GF, et al. Urinary 99m-Tc-diphosphonate excretion as a simple method to quantify bone metabolism. Scand J Clin Lab Invest. 1984;44:105–109
  65. Thomsen K, Nilas L, Mogensen T, et al. Determination of bone turnover by urinary excretion of 99m-Tc-MDP. Eur J Nucl Med. 1986;12:342–345
  66. Davie MWJ, Britton JM, Haddaway M, et al. 99mTc-MDP retention in osteoporosis: Relationship to other indices of bone cell activity and response to calcium and vitamin D therapy. Eur J Nucl Med. 1987;13:462–466
  67. Andrews GA, Gibbs WD, Morris AC. Whole-body counting. Semin Nucl Med. 1973;3:367–388
  68. Smith ML, Martin W, Fogelman I, et al. Relative distribution of disphosphonate between bone and soft tissue at 4 and 24 hours: Concise communication. J Nucl Med. 1982;24:208–211
  69. Schumichen C, Rempfle H, Wagner M, et al. The short-term fixation of radiopharmaceuticals in bone. Eur J Nucl Med. 1979;4:423–428
  70. Francis MD, Fogelman I. 99mTc-diphosphonate uptake mechanism on bone. In: Fogelman I editors. Bone Scanning in Clinical Practice. London: Springer-Verlag; 1986;p. 7–17
  71. Fogelman I, Pearson DW, Bessent RG, et al. A comparison of skeletal uptakes of three diphosphonates by whole-body retention: Concise communication. J Nucl Med. 1981;22:880–883
  72. Thomsen K, Johansen J, Nilas L, et al. Whole body retention of 99m-Tc-disphosphonate. Relation to biochemical indices of bone turnover and to total body calcium. Eur J Nucl Med. 1987;13:32–35
  73. Hyldstrup L, McNair P, Transbol I. GFR-corrected 24-hour whole body retention of diphosphonate: An improved index of bone metabolism. Scand J Clin Lab Invest. 1988;48:341–345
  74. Mosekilde L, Hasling C, Charles P, et al. Biphosphonate whole body retention test: Relations to bone mineralisation rate, renal function and metabolic bone disorders. Eur J Clin Invest. 1987;17:530–537
  75. Hyldstrup L. 24-hour whole body retention of 99mTc-methylene-diphosphonate in the assessment of bone formation. Methodological evaluation, clinical applications and comparison with serum alkaline phosphatase and serum osteocalcin. Dan Med Bull. 1989;36:349–358
  76. Charkes ND, Todd Makler P, Philips C. Studies of skeletal tracer kinetics. I. Digital computer, solution of a five-compartment model of [18F]fluoride kinetics in humans. J Nucl Med. 1978;19:1301–1309
  77. Charkes ND, Brookes M, Todd Makler P. Studies of skeletal tracer kinetics: II. Evaluation of a five-compartment model of [18F]fluoride kinetics in rats. J Nucl Med. 1979;20:1150–1157
  78. Sagar VV, Piccone JM, Charkes ND. Studies of skeletal tracer kinetics. III. Tc-99m(Sn)-methylene diphosphonate uptake in the canine tibia as a function of blood flow. J Nucl Med. 1979;20:1257–1261
  79. Todd Makler P, Charkes ND. Studies of skeletal tracer kinetics IV. Optimum time delay for Tc-99m(Sn) methylene disphosphonate bone imaging. J Nucl Med. 1980;21:641–645
  80. Charkes ND, Todd Makler P. Studies in skeletal tracer kinetics. V. Computer-simulated Tc-99m(Sn)methylene diphosphonate bone scan changes in certain systemic disorders. J Nucl Med. 1981;22:601–605
  81. McCarthy ID, Hughes SFP. Multiple tracer studies of bone uptake of 99mTc-MDP and 85Sr. Am J Physiol. 1989;256:H1261–H1265
  82. Hooper G, McCarthy ID, Wootton R, et al. Fluid spaces in the canine tibia. In: Arlet J, Ficat RP, Hungerford DS editor. Bone Circulation. Baltimore, MD: Williams & Wilkins; 1984;p. 204–206
  83. Charkes ND, Seigel JA. An analytical solution set for a four-compartment mixed mammillary/catenary model. Nucl Med Commun. 1999;20:575–580
  84. Charkes ND. Skeletal blood flow: Implications for bonescan interpretation. J Nucl Med. 1980;21:91–98
  85. Cousins C, Mohammadtaghi S, Mubasher M, et al. Clearance kinetics of solutes used to measure glomerular filtration rate. Nucl Med Commun. 1999;20:1047–1054
  86. Nisbet AP, Edwards S, Mashiter G, et al. Quantitation of Tc99m MDP retention during routine bone scanning. Nucl Med Commun. 1983;4:67–71
  87. Waller DG, Keast CM, Fleming JS, et al. Measurements of glomerular filtration rate with 99mTc-DTPA: Comparison of plasma clearance techniques. J Nucl Med. 1987;28:372–377
  88. Hamilton D, Miola UJ. Body surface area correction in single-sample methods of glomerular filtration rate estimation. Nucl Med Commun. 1999;20:273–278
  89. Evans AJ, Perkins AC, Wastie ML, et al. Diphosphonate space: A useful quantitative index of disease activity in patients undergoing HMDP treatment or Paget's disease. Eur J Nucl Med. 1991;18:757–759
  90. Stone MD, Marshall DH, Hosking DJ, et al. Bisphosphonate space measurement in Paget's disease of bone treated with APD. J Bone Miner Res. 1992;7:295–301
  91. Wootton R, Reeve J, Veall N. The clinical measurement of skeletal blood flow. Clin Sci Mol Med. 1976;50:261–268
  92. Reeve J, Hesp R. A model-independent comparison of the rates of uptake and short term retention of 47Ca and 85Sr in the skeleton. Calcif Tissue Res. 1976;22:183–189
  93. Reeve J, Wootton R, Hesp R. A new method for calculating the accretion rate of bone calcium and some observations on the suitability of strontium-85 as a tracer for bone calcium. Calcif Tissue Res. 1976;20:121–135
  94. Reeve J, Hesp R, Wootton R. A new tracer method for the calculation of bone formation and breakdown in osteoporosis and other, generalized skeletal disorders. Calcif Tissue Res. 1976;22:191–206
  95. Rehling M, Hyldstrup L, Henriksen JH. Arterio-venous concentration difference of [51Cr]EDTA after a single injection in man. Significance of renal function and local blood flow. Clin Physiol. 1989;9:279–288
  96. Reeve J, Arlot M, Wootton R, et al. Skeletal blood flow, iliac histomorphometry, and strontium kinetics in osteoporosis: A relationship between bone blood flow and corrected apposition rate. J Clin Endocrinol Metab. 1988;66:1124–1131
  97. Blake GM, Gray JM, Zivanovic MA, et al. Strontium-89 radionuclide therapy: A dosimetric study using impulse response function analysis. Br J Radiol. 1987;60:685–692
  98. Messa C, Goodman WG, Hoh CK, et al. Bone metabolic activity measured with positron emission tomography and [18F]fluoride ion in renal osteodystrophy: Correlation with bone histomorphometry. J Clin Endocrinol Metab. 1993;77:949–955
  99. Berding G, Burchert W, van den Hoff J, et al. Evaluation of the incorporation of bone grafts used in maxillofacial surgery with [18F]fluoride ion and dynamic positron emission tomography. Eur J Nucl Med. 1995;22:1133–1140
  100. Schiepers C, Nuyts J, Bormans G, et al. Fluoride kinetics of the axial skeleton measured in vivo with fluorine-18-fluoride PET. J Nucl Med. 1997;38:1970–1976
  101. Piert M, Zittel TT, Machulla H-J, et al. Blood flow measurements with [15O]H2O and [18F]fluoride ion PET in porcine vertebrae. J Bone Miner Res. 1998;13:1328–1336
  102. Cook GJR, Lodge MA, Blake GM, et al. Differences in skeletal kinetics between vertebral and humeral bone measured by 18F-fluoride positron emission tomography in postmenopausal women. J Bone Miner Res. 2000;15:763–769
  103. Cook GJR, Fogelman I. The role of positron emission tomography in skeletal disease. Semin Nucl Med. 2000;31:50–61
  104. Tothill P, MacPherson JN. Post-mortem migration of bone-seeking radionuclides in the rat and rabbit and its effect on estimates of bone uptake. Clin Sci Mol Med. 1978;55:221–223
  105. D'Addabbo A, Rubini G, Mele M, et al. A new method of assessing Tc-99m-MDP bone uptake from a bone scan image: Quantitative measurement of radioactivity in global skeletal region of interest. Nucl Med Commun. 1992;13:55–60
  106. Rubini G, Lauriero F, Rubini D, et al. Tc-99m-MDP global skeletal uptake and markers of bone metabolism in patients with bone disease. Nucl Med Commun. 1993;14:567–572
  107. Carnevale V, Frusciante V, Scillitani A, et al. Agerelated changes in the global skeletal uptake of technetium-99m methylene disphosphonate in healthy women. Eur J Nucl Med. 1996;23:1473–1477
  108. Kigami Y, Yamamoto I, Ohnishi H, et al. Age-related change of technetium-99m-HMDP distribution in the skeleton. J Nucl Med. 1996;37:815–818
  109. Brenner W, Bohuslavizki KH, Sieweke N, et al. Quantification of diphosphonate uptake based on conventional bone scanning. Eur J Nucl Med. 1997;24:1284–1290
  110. Front D, Israel O, Jerushalmi J, et al. Quantitative bone scintigraphy using SPECT. J Nucl Med. 1989;30:240–245
  111. Iosilevsky G, Israel O, Frenkel A, et al. A practical SPECT technique for quantitation of drug delivery to human tumors and organ absorbed radiation dose. Semin Nucl Med. 1989;19:33–46
  112. Israel O, Front D, Hardoff R, et al. In vivo SPECT quantitation of bone metabolism in hyperparathyroidism and thyrotoxicosis. J Nucl Med. 1991;32:1157–1161
  113. Israel O, Lubushitzky R, Frenkel A, et al. Bone turnover in cortical and trabecular bone in normal women and in women with osteoporosis. J Nucl Med. 1994;35:1155–1158
  114. Tsui BMW, Zhao X, Frey EC, et al. Quantitative single-photon emission computed tomography: Basics and clinical considerations. Semin Nucl Med. 1994;4:38–65
  115. Case JA, Licho R, King MA, et al. Bone SPECT of the spine: A comparison of attenuation correction techniques. J Nucl Med. 1999;40:604–613
  116. Tothill P, Hooper G. Bone blood flow and extraction ratios: Microspheres and bone seekers. In: Arlet J, Ficat RP, Hungerford DS editor. Bone Circulation. Baltimore, MD: Williams & Wilkins; 1984;p. 171–174
  117. Hughes S, Davies R, Khan R, et al. Fluid space in bone. Clinical Orthop. 1978;134:332–341
  118. McCarthy ID, Hughes SPF. The role of skeletal blood flow in determining the uptake of 99mTc-methylene diphosphonate. Calcif Tissue Int. 1983;35:508–511
  119. Peters AM, Jamar F. The importance of endothelium and interstitial fluid in nuclear medicine. Eur J Nucl Med. 1998;25:801–815
  120. Renkin EM. Transport of potassium-42 from blood to tissue in isolated mammalian skeletal muscles. Am J Physiol. 1959;197:1205–1210
  121. Hughes SPF, Kelly PJ. The mechanism of ion transfer in bone. In: Arlet J, Ficat RP, Hungerford DS editor. Bone Circulation. Baltimore, MD: Williams & Wilkins; 1984;p. 207–212
  122. Tothill P, MacPherson JN. Liminations of radioactive microspheres as tracers for bone blood flow and extraction ratio studies. Calcif Tissue Int. 1980;31:261–265
  123. Tothill P, Hooper G. Invalidity of single-passage measurements of the extraction of bone-seeking tracers in rats and rabbits. J Orthop Res. 1984;2:75–79
  124. Wootton R. The single-passage extraction of 18F in rabbit bone. Clin Sci Mol Med. 1974;47:73–77
  125. Lemon GJ, Davies DR, Hughes SPF, et al. Transcapillary exchange and retention of fluoride, strontium, EDTA sucrose and anitipyrine in blood. Calcif Tissue Int. 1980;31:173–181
  126. McCarthy ID, Hughes SPF. Extraction of 99mTc-methylene diphosphonate as a function of bone blood flow. In: Arlet J, Ficat RP, Hungerford DS editor. Bone Circulation. Baltimore, MD: Williams & Wilkins; 1984;p. 167–170
  127. Einhorn TA, Vigorita VJ, Aairon A. Localization of technetium-99m methylene diphosphonate in bone using microautoradiography. J Orthop Res. 1986;4:180–187
  128. Tilden RL, Jackson J, Enneking WF, et al. 99mTc-polyphosphate: Histological localization in human femurs by autoradiography. J Nucl Med. 1973;14:576–578
  129. Guillemart A, Bisnard J-C, Le Pape A, et al. Skeletal uptake of pyrophosphate labeled with technetium-95m and technetium-96 as evaluated by autoradiography. J Nucl Med. 1978;19:895–899
  130. Light TR, McKinstry MP, Schitzer J, et al. Bone blood flow: Regional variation with skeletal maturation. In: Arlet J, Ficat RP, Hungerford DS editor. Bone Circulation. Baltimore MD: Williams & Wilkins; 1984;p. 178–185
  131. Lavender JP, Khan RAA, Hughes SPF. Blood flow and tracer uptake in normal and abnormal canine bone: Comparisons with Sr-85 microspheres, Kr-81m, and Tc-99m MDP. J Nucl Med. 1979;20:413–418
  132. Francis MD, Ferguson DL, Tofe AJ, et al. Comparative evaluation of three diphosphonates: In vitro adsorption (C-14 labeled) and in vivo osteogenic uptake (Tc-99m complexed). J Nucl Med. 1980;21:1185–1189
  133. Budd RS, Hodgson GS, Hare WSC. The relation of radionuclide uptake by bone to the rate of calcium mineralization. I: Experimental studies using 45Ca, 32P and 99mTc-MDP. Br J Radiol. 1989;62:314–317
  134. Tofe AJ, Francis MD. Optimization of the ratio of stannous tin: Ethane-1-hydroxyl-1,1-disphosphonate for bone scanning with 99mTc-pertechnetate. J Nucl Med. 1974;15:69–74
  135. Langevelde A van, Driessen OMJ, Pauwels EKJ, et al. Aspects of 99mtechnetium binding from an ethane-1-hydroxy-1,1-diphosphonate-99mTc complex to bone. Eur J Nucl Med. 1977;2:47–51
  136. Hambright P, McRae J, Valk PE, et al. Chemistry of technetium radiopharmaceuticals. I. Exploration of the tissue distribution and oxidation state consequences of Technetium (IV) in Tc-Sn-Gluconate and Tc-Sn-EHDP using carrier free 99Tc. J Nucl Med. 1975;16:478–482
  137. Grynpas MD. Fluoride effects on bone crystals. J Bone Miner Res. 1990;5(suppl 1):S169–S175
  138. Bang S, Baud CA. Topographical distribution of fluoride in iliac bone of a fluoride treated osteoporotic patient. J Bone Miner Res. 1990;5(suppl 1):S87–S89
  139. Neuman WF, Neuman MW. The chemical dynamics of bone mineral. In: Chicago, IL: University of Chicago Press; 1958;p. 75–100
  140. Budinger TF. PET instrumentation: What are the limits?. Semin Nucl Med. 1998;28:247–267

PII: S0001-2998(01)80030-1

doi: 10.1053/snuc.2001.18742

Seminars in Nuclear Medicine
Volume 31, Issue 1 , Pages 28-49 , January 2001

Article Tools